A Single Ascending Dose Study of Safety and Tolerability of STA363 Compared to Placebo in 15 Patients With Chronic Discogenic Low Back Pain

NCT ID: NCT03055845

Last Updated: 2020-02-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-03-27
• Study Completion Date: 2019-08-29

Brief Summary

A phase I, randomized, double-blinded, placebo-controlled, single ascending dose study to investigate the safety, local tolerability and transformation of nucleus pulposus following intradiscal injection of STA363 or placebo in patients with discogenic low back pain.

15 patients will participate in either of 3 dose groups, each comprising 5 patients:

• Group 1: STA363 dose 1 (3 patients) or placebo (2 patients)
• Group 2: STA363 dose 2 (3 patients) or placebo (2 patients)
• Group 3: STA363 dose 3 (3 patients) or placebo (2 patients)

Conditions

Low Back Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

STA363 dose 1

Group Type: EXPERIMENTAL

STA363

Intervention Type: DRUG

STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.

STA363 dose 2

Group Type: EXPERIMENTAL

STA363

Intervention Type: DRUG

STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.

STA363 dose 3

Group Type: EXPERIMENTAL

STA363

Intervention Type: DRUG

STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.

Interventions

STA363

STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.

Intervention Type: DRUG

Placebo

Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Signed informed consent prior to any study-related procedures
• Chronic discogenic low back pain present for more than 6 months prior to the screening visit
• 20 to 60 years of age at the screening visit
• Insufficient response to at least 6 months of non-operative treatment (analgesics and/or antiinflammatory medication, physiotherapy etc.)
• A single lumbar disc appropriate for treatment at L3/4 to L5/S1, based on clinical evaluation by the investigator
• Pfirrmann grade II-III
• Ability to understand the written and verbal information about the study

Exclusion Criteria

• Treatment with any investigational product within 3 months prior to the screening visit
• More than one painful intervertebral disc
• A painful intervertebral disc above L3/4 level
• Current infection or prior history of spinal infection (e.g., discitis, septic arthritis, epidural abscess) or an active systemic infection
• Previous lumbar spine surgery
• Previous disc invasive treatment procedures at the affected level(s) (e.g., intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation)
• Pfirrmann grade I, IV and V
• Evidence of prior lumbar vertebral body fracture or trauma
• Need for spinal decompression assessed by the investigator
• Presence of disc extrusion or sequestration
• Patients previously included in the study
• Patients suffering from psychosomatic pain in the opinion of the investigator
• Referred leg pain of compressive origin
• Known alcohol and/or drug abuse
• Severe intercurrent illness (e.g. rheumatic disease or chronic pain syndrome) or concomitant treatment (e.g. immunosuppressive drugs), which, in the opinion of the investigator, may put the patient at risk when participating in the study, or affect the patient's ability to take part in the study
• Clinically significant abnormalities in clinical chemistry or haematology parameters as assessed by the investigator
• Pregnant or lactating females or intention to become pregnant within the study period
• Known allergy to any of the components of the drug product or placebo
• Known opioid allergy or intolerance
• Patients requiring treatment with warfarin or other anticoagulant therapy
• Unwillingness to refrain from treatment with non-steroidal anti-inflammatory drugs (NSAIDs) within 5 days before the planned study treatment
• Body weight less than 50 kg

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Stayble Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Stockholm Spine Center, Löwenströmska Sjukhuset

Upplands Vasby, , Sweden

Countries

Sweden

Other Identifiers

2015-004812-39

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

STA-01

Identifier Type: -

Identifier Source: org_study_id